Biogen’s Tau Antibody Fails In PSP, But Alzheimer’s Studies Continue

 
• By Mandy Jackson

Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing. 

Diagnosis Progressive Supranuclear Palsy, pills and stethoscope.
Gosuranemab is at least the second anti-tau agent to fail in PSP this year. • Source: Shutterstock

More from Clinical Trials

More from R&D